Combination of Targeted Radiotherapy with Other Therapeutic Modalities for Cancer Treatment

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: closed (20 July 2024) | Viewed by 1140

Special Issue Editors


E-Mail Website
Guest Editor
Nanomaterials for Biomedical Applications, Italian Institute of Technology, via Morego 30, 16163 Genoa, Italy
Interests: nanomedicine; radiochemistry; theranostics; molecular imaging; targeted therapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Perelman School of Medicine, University of Pennsylvania, 815 Stellar-Chance, 422 Curie Boulevard, Philadelphia, PA 19104, USA
Interests: theranostics; cancer imaging and therapy; medicinal chemistry

Special Issue Information

Dear Colleagues,

Cancer is a complex disease that requires a multifaceted approach to treatment. Targeted radiotherapy has emerged as a promising therapeutic modality for cancer treatment, as it selectively delivers radiation to cancer cells while minimizing damage to healthy tissues; however, the use of targeted radiotherapy alone may not always provide sufficient efficacy in controlling the disease. Thus, the combination of targeted radiotherapy with other therapeutic modalities has gained increasing attention in recent years.

This Special Issue in Pharmaceutics focuses on the combination of targeted radiotherapy with other therapeutic modalities for cancer treatment, including, but not limited to, chemotherapy, immunotherapy, phototherapies, and thermal therapies. This Special Issue aims to highlight the potential of these combination therapies in improving treatment efficacy, reducing toxicity, and overcoming treatment resistance. One promising approach to combining targeted radiotherapy with other therapeutic modalities involves the use of multifunctional nanoparticles. These nanoparticles can be designed to carry both therapeutic and diagnostic payloads, allowing for the targeted delivery of multiple therapies to cancer cells while minimizing damage to healthy tissues.

The goal of this Special Issue is to provide a comprehensive overview of the latest possibilities for the combination of radiotherapy with other therapeutic modalities for cancer treatment, particularly in the context of multifunctional nanoparticles. This Special Issue seeks original research articles, review articles, and clinical studies that investigate the combinatorial therapy approach.

Dr. Nisarg Soni
Dr. Swarbhanu Sarkar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • targeted radionuclide therapy
  • multimodal nanoparticles
  • cancer
  • personalized medicine
  • theranostics
  • nanomedicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 2696 KiB  
Review
Treating Deep-Seated Tumors with Radiodynamic Therapy: Progress and Perspectives
by Shengcang Zhu, Siyue Lin and Rongcheng Han
Pharmaceutics 2024, 16(9), 1135; https://doi.org/10.3390/pharmaceutics16091135 - 28 Aug 2024
Viewed by 746
Abstract
Radiodynamic therapy (RDT), as an emerging cancer treatment method, has attracted attention due to its remarkable therapeutic efficacy using low-dose, high-energy radiation (such as X-rays) and has shown significant potential in cancer treatment. The RDT system typically consists of scintillators and photosensitizers (PSs). [...] Read more.
Radiodynamic therapy (RDT), as an emerging cancer treatment method, has attracted attention due to its remarkable therapeutic efficacy using low-dose, high-energy radiation (such as X-rays) and has shown significant potential in cancer treatment. The RDT system typically consists of scintillators and photosensitizers (PSs). Scintillators absorb X-rays and convert them to visible light, activating nearby PSs to generate cytotoxic reactive oxygen species (ROS). Challenges faced by the two-component strategy, including low loading capacity and inefficient energy transfer, hinder its final effectiveness. In addition, the tumor microenvironment (TME) with hypoxia and immunosuppression limits the efficacy of RDTs. Recent advances introduce one-component RDT systems based on nanomaterials with high-Z metal elements, which effectively inhibit deep-seated tumors. These novel RDT systems exhibit immune enhancement and immune memory, potentially eliminating both primary and metastatic tumors. This review comprehensively analyzes recent advances in the rational construction of RDTs, exploring their mechanisms and application in the treatment of deep-seated tumors. Aimed at providing a practical resource for oncology researchers and practitioners, the review offers new perspectives for potential future directions in RDT research. Full article
Show Figures

Figure 1

Back to TopTop